TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05463263: A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Sponsor: Step Pharma, SAS · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,924,230

Rescue Site Savings

+$1,256,640

Unlock Full NCT05463263 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05463263 Rescue Dossier →